Literature DB >> 20394797

In vitro deprivation of CD8(+)CD57(+)T cells promotes the malignant growth of bone marrow colony cells in patients with lower-risk myelodysplastic syndrome.

Zhang Zheng1, Zhang Qianqiao, He Qi, Xu Feng, Chang Chunkang, Li Xiao.   

Abstract

OBJECTIVE: CD8(+)T lymphocytes have inhibitory effects on the proliferation of malignant clones in myelodysplastic syndrome (MDS). The exact CD8(+)T subset involved in the regulation of MDS and the target clones of CD8(+)T lymphocytes has not been studied. We investigated the effect of activated CD8(+)T (CD8(+)CD57(+)) lymphocytes on colony formation (in particular, malignant colony formation) during MDS in vitro.
MATERIALS AND METHODS: Bone marrow mononuclear cells (BMNCs) from a total of 59 MDS patients were subjected to magnetic-activated cell sorting to separate CD8(+)CD57(+)T lymphocytes. BMNCs were cultured without CD8(+)CD57(+)T cells or cocultured with a 1:4 ratio of CD8(+)CD57(+)T cells to study the association between stem/progenitor cell colony formation and the existence of activated CD8(+) T cells, as well as the polarization of T cells towards Tc1. In addition, the fluorescence in situ hybridization method was used to detect bone marrow cells carrying abnormal karyotypes, and the proportion of abnormal cells among BMNCs was calculated before and after T-cell deprivation culture in vitro. Crossing cultures between MDS patients and normal volunteer was performed. The impact of effector CD8(+)T cells on the malignant growth of BMNCs was closely examined.
RESULTS: After deprivation of CD8(+)CD57(+)T cells, BMNCs from 33 MDS patients formed colonies in the culture media. The average number cells in the granulocyte and monocyte colony-forming units (CFU-GM) was 40.3/4 x 10(5), and the average number of cells in the erythroid colony-forming unit (CFU) was 10.4/4 x 10(5). These totals were significantly lower than those in the normal control group after deprivation of CD8(+)CD57(+)T cells (CFU-GM 83.4/4 x 10(5) cells, erythroid CFU 32.8/4 x 10(5) cells; p < 0.001). After add-back of CD8(+)CD57(+) T cells (four times), none of the BMNCs cultures from any of the 59 MDS patients formed colonies in vitro. Additionally, in 33 MDS patients whose BMNCs formed colonies after T-cell deprivation, the bone marrow Tc1/Tc2 ratio was positively correlated with CFU-GM count (r = 0.443, p < 0.05). Crossing cultures indicated that CD8(+)CD57(+) T cells from MDS patients cocultured with BMNC from normal donor did not show inhibition to colony-forming. In 15 MDS patients with abnormal karyotypes, deprivation of CD8(+)CD57(+)T cells significantly increased the proportion of abnormal cells from 43.8% to 56.3% in BMNC culture (p < 0.001).
CONCLUSION: Effector CD8(+)T lymphocytes inhibit bone marrow hematopoiesis in MDS patients; target cells were primarily cells with abnormal karyotypes. 2010 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20394797     DOI: 10.1016/j.exphem.2010.04.002

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  10 in total

Review 1.  Microenvironmental Features Driving Immune Evasion in Myelodysplastic Syndromes and Acute Myeloid Leukemia.

Authors:  Georgios Petros Barakos; Eleftheria Hatzimichael
Journal:  Diseases       Date:  2022-06-10

Review 2.  Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes.

Authors:  I Gañán-Gómez; Y Wei; D T Starczynowski; S Colla; H Yang; M Cabrero-Calvo; Z S Bohannan; A Verma; U Steidl; G Garcia-Manero
Journal:  Leukemia       Date:  2015-03-12       Impact factor: 11.528

3.  T-cell receptor Vβ skewing frequently occurs in refractory cytopenia of childhood and is associated with an expansion of effector cytotoxic T cells: a prospective study by EWOG-MDS.

Authors:  A M Aalbers; M M van den Heuvel-Eibrink; I Baumann; H B Beverloo; G J Driessen; M Dworzak; A Fischer; G Göhring; H Hasle; F Locatelli; B De Moerloose; P Noellke; M Schmugge; J Stary; A Yoshimi; M Zecca; C M Zwaan; J J M van Dongen; R Pieters; C M Niemeyer; V H J van der Velden; A W Langerak
Journal:  Blood Cancer J       Date:  2014-05-02       Impact factor: 11.037

4.  DNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignancies.

Authors:  Carole Le Pogam; Satyananda Patel; Petra Gorombei; Laura Guerenne; Patricia Krief; Nader Omidvar; Nilgun Tekin; Elena Bernasconi; Flore Sicre; Marie-Helene Schlageter; Martine Chopin; Maria-Elena Noguera; Robert West; Ansu Abu; Vikram Mathews; Marika Pla; Pierre Fenaux; Christine Chomienne; Rose Ann Padua
Journal:  Oncotarget       Date:  2015-10-20

5.  The Systemic Profile of Soluble Immune Mediators in Patients with Myelodysplastic Syndromes.

Authors:  Astrid Olsnes Kittang; Kristoffer Sand; Annette Katharina Brenner; Kristin Paulsen Rye; Øystein Bruserud
Journal:  Int J Mol Sci       Date:  2016-07-05       Impact factor: 5.923

6.  Altered Spatial Composition of the Immune Cell Repertoire in Association to CD34+ Blasts in Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia.

Authors:  Marcus Bauer; Christoforos Vaxevanis; Haifa Kathrin Al-Ali; Nadja Jaekel; Christin Le Hoa Naumann; Judith Schaffrath; Achim Rau; Barbara Seliger; Claudia Wickenhauser
Journal:  Cancers (Basel)       Date:  2021-01-07       Impact factor: 6.639

Review 7.  The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification.

Authors:  Xiaohuan Peng; Xiaofeng Zhu; Tianning Di; Futian Tang; Xiaojia Guo; Yang Liu; Jun Bai; Yanhong Li; Lijuan Li; Liansheng Zhang
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

8.  Distinct clinical and experimental characteristics in the patients younger than 60 years old with myelodysplastic syndromes.

Authors:  Xiao Li; Zhi-jian Xiao; Chun-kang Chang; Feng Xu; Ling-yun Wu; Qi He; Ze-feng Xu; Lu-xi Song; Zheng Zhang; Li-yu Zhou; Ji-ying Su; Xi Zhang; Juan Guo
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

9.  Establishment and validation of an updated diagnostic FCM scoring system based on pooled immunophenotyping in CD34+ blasts and its clinical significance for myelodysplastic syndromes.

Authors:  Feng Xu; Xiao Li; Chun-Kang Chang; Juan Guo; Ling-Yun Wu; Qi He; Zheng Zhang; Yang Zhu; Shu-Chen Gu; Wen-Hui Shi; Lu-Xi Song; Ji-Ying Su; Li-Yu Zhou; Xi Zhang; Dong Wu
Journal:  PLoS One       Date:  2014-02-18       Impact factor: 3.240

Review 10.  Immune Mechanisms in Myelodysplastic Syndrome.

Authors:  Andreas Glenthøj; Andreas Due Ørskov; Jakob Werner Hansen; Sine Reker Hadrup; Casey O'Connell; Kirsten Grønbæk
Journal:  Int J Mol Sci       Date:  2016-06-15       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.